- 2024.
- 2023.
- 2022.
- 2021.
- 2020.
- 2019.
- 2018.
- 2017.
- 2016.
- 2015.
- 2014.
- 2013.
- 2012.
- 2011.
- 2010.
- 2009.
- 2008.
- 2007.
- 2006.
- 2005.
- 2004.
- 2003.
- 2002.
- 2001.
- 2000.
- 1999.
- 1998.
- 2024.
- 2023.
- 2022.
- 2021.
- 2020.
- 2019.
- 2018.
- 2017.
- 2016.
- 2015.
- 2014.
- 2013.
- 2012.
- 2011.
- 2010.
- 2009.
- 2008.
- 2007.
- 2006.
- 2005.
- 2004.
- 2003.
- 2002.
- 2001.
- 2000.
- 1999.
- 1998.
2013.
-
- Dec.24.2013
- ONO Files for Regulatory Approval of "Nivolumab (ONO-4538/BMS-936558)" for Treatment of Malignant Melanoma(24 KB)
-
- Dec.16.2013
- FDA Advisory Committee Recommends the Investigational SGLT2 Inhibitor Dapagliflozin for the Treatment of Type 2 Diabetes in Adults(423 KB)
-
- Dec.13.2013
- Ono Establishes a Local Subsidiary in South Korea(63 KB)
-
- Dec.09.2013
- Clinical Trial Application submitted for Phase I study of ONO-7268MX2, peptide-cocktail vaccine for hepatocellular carcinoma(87 KB)
-
- Dec.03.2013
- AstraZeneca and Ono Enter Co-promotion Agreement in Japan for Dapagliflozin(94 KB)
-
- Nov.22.2013
- Approval for Additional Indication of Onoact® 50 for injection, Short-Acting Selective β1 Blocker in Japan(117 KB)
-
- Nov.14.2013
- Results of Phase II/III Study of ONO-2745/CNS 7056, a Short-acting General Anesthetic(90 KB)
-
- Nov.05.2013
- Announcement on Financial Results for FY2013 2Q
-
- Oct.28.2013
- Fully Human Anti-PD-1 Antibody "Nivolumab (ONO-4538/BMS-936558)" Updated Results from a Phase 1 Study in Patients with NSCLC Presented at 15th World Conference on Lung Cancer(84 KB)
-
- Oct.22.2013
- Ono Enters into License Agreement with Valeant(88 KB)
-
- Oct.09.2013
- Ono Establishes a Local Subsidiary in South Korea(42 KB)
-
- Oct.01.2013
- Fully Human Anti-PD-1 Antibody "Nivolumab (ONO-4538/BMS-936558)" Result from Phase II Study in Patients with Melanoma Presented at European Cancer Congress 2013(64 KB)
-
- Sep.27.2013
- Decision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced(58 KB)
-
- Aug.27.2013
- Rheumatoid Arthritis Drug ORENCIA® SC 125mg Syringe 1mL Launched in Japan(135 KB)
-
- Aug.13.2013
- Ono Pharmaceutical and MSD applied for partial change in indications of "Sitagliptin", to add "type 2 diabetes"(46 KB)
-
- Aug.06.2013
- Application Submission for Approval for the Stability-Improved Formulation of Limaprost,an Oral Prostaglandin E1 Analogue in Japan(28 KB)
-
- Aug.02.2013
- Announcement on Financial Results for FY2013 1Q
-
- Aug.02.2013
- "Glactiv® tablets" for the oral treatment of type 2 diabetes Contraindication was removed and replaced by careful administration in patients with severe renal insufficiency(109 KB)
-
- Jul.05.2013
- Subcutaneous (SC) formulation of ORENCIA® (abatacept) Results of Year Two Data from AMPLE Study in Patients with Moderate to Severe Rheumatoid Arthritis Presented at the European League Against Rheumatism (EULAR) Annual Congress(296 KB)
-
- Jun.28.2013
- Rheumatoid Arthritis Drug ORENCIA® SC 125mg Syringe 1mL Approved for Production and Distribution(91 KB)
-
- Jun.04.2013
- Bristol-Myers and Ono Pharmaceutical to Announce Lifting of Approval Conditions (Completion of PMS: "All-Case Surveillance") and Start of Co-Promotion(71 KB)
-
- Jun.03.2013
- Fully Human Anti-PD-1 Antibody "ONO-4538/BMS-936558" Results from Phase 1 Study in Patients with Melanoma Presented at Annual Meeting of the American Society of Clinical Oncology (ASCO)(219 KB)
-
- May.16.2013
- Detailed Results of Phase III Trial of L-BLP25 in Patients with Non-Small Cell Lung Cancer (START) to be Presented at ASCO(67 KB)
-
- May.13.2013
- Announcement on Financial Results for FY2012
-
- May.13.2013
- Partial Amendment of Articles of Incorporation(17 KB)
-
- May.13.2013
- Voluntary adoption of International Financial Reporting Standards (IFRS)(114 KB)
-
- May.09.2013
- Announcement on Candidates of Members of the Board of Directors,Corporate Auditors and Corporate Officers(14 KB)
-
- May.08.2013
- Ono and Dainippon Sumitomo reach agreement on expanding business relating to Limaprost into China(16 KB)
-
- Apr.18.2013
- Ono Enters into License Agreement with Bial(10 KB)
-
- Feb.20.2013
- Additional Indication Application filed for Onoact® 50 for injection,Short-Acting Selective β1 Blocker in Japan(80 KB)
-
- Feb.04.2013
- Announcement on Financial Results for FY2012 3Q
-
- Jan.25.2013
- Discontinuation of Development for the Additional Indication of Carpal-Tunnel Syndrome, for Limaprost, an Oral Prostaglandin E1 Analogue(13 KB)